Gastroenterology and Hepatology Unit, Weill Bugando School of Medicine, Catholic University of Heath and Allied Sciences and Bugando Hospital Mwanza, P.O. BOX 1464, Mwanza, Tanzania.
Weill Cornell Medicine-Qatar, Doha, Qatar.
BMC Infect Dis. 2018 Apr 24;18(1):193. doi: 10.1186/s12879-018-3099-4.
Worldwide Helicobacter pylori (H.pylori) treatment is of great challenge due to increased antibiotic resistance. The burden of H. pylori antibiotic resistance in Africa is high with unclear information regarding the real magnitude. This systematic review and meta-analysis was conducted to investigate the magnitude of H.pylori antibiotic resistance in Africa to gain insight of the extent of the problem among H.pylori naïve treatment patients.
The search was performed in the academic databases, Embase, PubMed, Web of Science and Africa Wide Information. ProQuest Dissertation and Theses, Scopus, Ethos, Africa Index Medicus (WHO), BioMed Central Proceedings, BASE, British Library, Open grey, Library of Congress and the New York Academy of Grey Literature Report were additionally searched for grey literature. Published articles from Africa on H.pylori antibiotic resistance between 1986 and June 2017 were systematically reviewed to estimate the H. pylori extent of resistance to macrolides, quinolones, amoxicillin, tetracycline and metronidazole.
In 26 articles a total of 2085 isolates were tested for metronidazole, 1530 for amoxicillin, 1277 for tetracycline, 1752 for clarithromycin and 823 for quinolones.The overall pooled proportion of H.pylori resistance to quinolones, clarithromycin, tetracycline, metronidazole and amoxicillin were: (17.4%, 95%CI 12.8 - 21.9), (29.2%, 95%CI:26.7-31.8), (48.7%, 95%CI: 44.5-52.9), (75.8%, 95% CI: 74.1-.77.4) and (72.6%, 95% CI: 68.6-76.6), respectively. The commonest mutation detected were A2143G (49/97) for clarithromycin, RdxA (41/56) for metronidazole and D87I (16/40) for quinolones.
Prevalence of metronidazole, clarithromycin, and amoxicillin resistance is high in developing world including Africa. This could impair the first line triple therapy of the H.pylori infection. There is a need of conducting surveillance of H.pylori susceptibility pattern in Africa for dual and triple resistance which can be used for the empirical treatment.
由于抗生素耐药性的增加,全球范围内幽门螺杆菌(H.pylori)的治疗面临巨大挑战。非洲的 H. pylori 抗生素耐药性负担很高,但关于实际耐药程度的信息尚不清楚。本系统评价和荟萃分析旨在调查非洲 H.pylori 抗生素耐药性的程度,以了解 H.pylori 初治患者中该问题的严重程度。
在学术数据库 Embase、PubMed、Web of Science 和 Africa Wide Information 中进行检索。此外,还在 ProQuest 博士论文和论文、Scopus、Ethos、非洲医学索引(世界卫生组织)、生物医学中心会议录、BASE、大英图书馆、开放灰色、美国国会图书馆和纽约灰色文献报告中搜索灰色文献。对 1986 年至 2017 年 6 月期间在非洲发表的关于 H.pylori 抗生素耐药性的文章进行系统评价,以估计 H. pylori 对大环内酯类、喹诺酮类、阿莫西林、四环素和甲硝唑的耐药程度。
在 26 篇文章中,共有 2085 株分离株检测了甲硝唑、1530 株检测了阿莫西林、1277 株检测了四环素、1752 株检测了克拉霉素和 823 株检测了喹诺酮类药物。H.pylori 对喹诺酮类、克拉霉素、四环素、甲硝唑和阿莫西林的耐药总体汇总比例分别为:(17.4%,95%CI 12.8-21.9)、(29.2%,95%CI:26.7-31.8)、(48.7%,95%CI:44.5-52.9)、(75.8%,95%CI:74.1-77.4)和(72.6%,95%CI:68.6-76.6)。检测到的最常见突变是克拉霉素的 A2143G(49/97)、甲硝唑的 RdxA(41/56)和喹诺酮类的 D87I(16/40)。
发展中国家包括非洲的甲硝唑、克拉霉素和阿莫西林耐药率很高。这可能会损害 H.pylori 感染的一线三联疗法。需要对非洲的 H.pylori 药敏模式进行监测,以发现双重和三重耐药性,这可用于经验性治疗。